Healthcare ETFs provide diversified exposure to a defensive sector driven by innovation, and IXJ and VHT rank among the most followed choices. Both track healthcare equity indexes passively, yet they differ in geographic reach, fees, and concentration levels. This matters for investors considering a global healthcare allocation versus a U.S.-only approach, especially when assessing relative performance and current market positioning. From what I see, understanding the distinctions in holdings, momentum, and risk can clarify which option aligns better with a given strategy.
IXJ, the iShares Global Healthcare ETF, tracks the S&P Global 1200 Health Care Sector Index and holds exposure to more than 100 healthcare companies around the world. The portfolio leans heavily toward pharmaceuticals, biotech, and life sciences, with a smaller allocation to healthcare equipment and services. Even with its global mandate, U.S. large-cap names exert the strongest influence. In recent weeks, IXJ has traded in the upper part of its 52-week range and delivered a solid YTD gain in the mid-to-high teens. Its momentum ranking within the healthcare sector category improved markedly over the past quarter, indicating stronger relative strength. The fund carries an expense ratio near 0.4% and a relatively low three-year beta, consistent with the defensive nature of its holdings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
VHT, the Vanguard Health Care ETF, follows the MSCI US Investable Market Health Care 25/50 Index and focuses exclusively on U.S.-listed healthcare companies across large-, mid-, and small-cap segments. Top holdings include major U.S. pharmaceutical, biotech, and health-insurance names such as Eli Lilly, Johnson & Johnson, AbbVie, Merck, and UnitedHealth Group. Over recent weeks, VHT has also traded near the upper end of its 52-week range amid broad strength in U.S. healthcare equities. Its YTD return has edged slightly ahead of IXJ, supported by concentration in high-momentum U.S. pharmaceutical leaders. The fund benefits from a low expense ratio around 0.10% and significantly larger assets under management, which supports strong liquidity and tight spreads. Its U.S.-only focus, however, means it misses international healthcare growth opportunities.
The key difference between the two funds lies in geographic scope. IXJ combines U.S. and international exposure, which can help diversify single-country regulatory and policy risks, whereas VHT concentrates entirely on the U.S. healthcare sector. On cost, VHT is notably cheaper, with an expense ratio roughly one-quarter that of IXJ, and its larger AUM supports higher liquidity. In terms of recent momentum, both have rallied, though the drivers vary. VHT has benefited from gains concentrated in a handful of large U.S. pharmaceutical and biotech leaders, delivering strong returns alongside higher single-name concentration. IXJ, by contrast, has shown sharper improvement in relative strength versus its healthcare-fund peers, pointing to a broadening and accelerating trend. Risk profiles remain broadly similar, though IXJ’s lower beta and diversified country mix may provide a somewhat smoother ride, while VHT’s focused U.S. allocation offers purer exposure to domestic healthcare strength.
Based on factors such as trend consistency, relative momentum, diversification, and positioning, Tickeron’s AI currently leans toward IXJ. The fund’s sharp improvement in relative strength within its healthcare category signals an accelerating, well-supported trend, while its global mandate widens the pool of potential growth drivers beyond a single market. VHT remains a compelling lower-cost option with strong U.S. exposure, but its heavier concentration and slightly less favorable momentum trajectory place it marginally behind in this comparison. This assessment is probabilistic rather than definitive and reflects current market conditions, which can shift.
In my research process, I frequently rely on Tickeron’s Trending AI Robots to gauge market positioning. These systems help identify trends across thousands of tickers, providing a data-backed view that complements traditional analysis. For those looking at funds like IXJ and VHT, checking the trending bots can add valuable perspective on how AI trading systems are aligning with current conditions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
IXJ saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 52 instances where the indicator turned negative. In 40 of the 52 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 77%.
The 10-day RSI Indicator for IXJ moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 27 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 68 cases where IXJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IXJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
IXJ broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on IXJ as a result. In 66 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
IXJ moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IXJ crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where IXJ advanced for three days, in 256 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 218 of 263 cases where IXJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows